XNASPRCT
Market cap4.59bUSD
Jan 03, Last price
84.30USD
1D
1.37%
1Q
16.02%
IPO
134.75%
Name
PROCEPT BioRobotics Corp
Chart & Performance
Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
IPO date
Sep 15, 2021
Employees
428
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | |||||
Revenues | 136,191 81.55% | 75,014 117.60% | |||
Cost of revenue | 113,588 | 66,910 | |||
Unusual Expense (Income) | |||||
NOPBT | 22,603 | 8,104 | |||
NOPBT Margin | 16.60% | 10.80% | |||
Operating Taxes | 6,430 | ||||
Tax Rate | 79.34% | ||||
NOPAT | 22,603 | 1,674 | |||
Net income | (105,897) 13.16% | (93,584) 50.01% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 161,705 | 8,826 | |||
BB yield | -8.17% | -0.48% | |||
Debt | |||||
Debt current | 1,683 | 2,129 | |||
Long-term debt | 103,703 | 101,292 | |||
Deferred revenue | |||||
Other long-term liabilities | 517 | 1,779 | |||
Net debt | (151,836) | (121,476) | |||
Cash flow | |||||
Cash from operating activities | (108,003) | (80,382) | |||
CAPEX | (25,206) | (2,653) | |||
Cash from investing activities | (25,206) | (2,653) | |||
Cash from financing activities | 167,795 | 3,612 | |||
FCF | (28,246) | (31,251) | |||
Balance | |||||
Cash | 257,222 | 221,859 | |||
Long term investments | 3,038 | ||||
Excess cash | 250,412 | 221,146 | |||
Stockholders' equity | (454,488) | (348,681) | |||
Invested Capital | 814,961 | 624,020 | |||
ROIC | 3.14% | 0.38% | |||
ROCE | 6.27% | 2.94% | |||
EV | |||||
Common stock shares outstanding | 47,255 | 44,400 | |||
Price | 41.91 0.89% | 41.54 66.09% | |||
Market cap | 1,980,457 7.38% | 1,844,376 68.85% | |||
EV | 1,828,621 | 1,722,900 | |||
EBITDA | 26,410 | 10,945 | |||
EV/EBITDA | 69.24 | 157.41 | |||
Interest | 3,995 | 5,183 | |||
Interest/NOPBT | 17.67% | 63.96% |